Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug

Angew Chem Int Ed Engl. 2002 Mar 1;41(5):759-61. doi: 10.1002/1521-3773(20020301)41:5<759::aid-anie759>3.0.co;2-7.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bronchial Neoplasms / drug therapy
  • Bronchial Neoplasms / pathology
  • Carcinoma, Pancreatic Ductal / drug therapy
  • Carcinoma, Pancreatic Ductal / pathology
  • Cell Division / drug effects
  • Cyclopropanes / administration & dosage
  • Cyclopropanes / chemistry
  • Cyclopropanes / therapeutic use*
  • Enzyme Therapy*
  • Female
  • Galactosides / chemistry
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / therapeutic use*
  • Indoles / administration & dosage
  • Indoles / chemistry
  • Indoles / therapeutic use*
  • Inhibitory Concentration 50
  • Male
  • Mice
  • Mice, SCID
  • Neoplasms / drug therapy*
  • Prodrugs / administration & dosage
  • Prodrugs / therapeutic use
  • Prodrugs / toxicity
  • Tumor Cells, Cultured
  • beta-Galactosidase

Substances

  • 1,2,9,9a-tetrahydrocyclopropa(c)benz(e)indol-4-one
  • Cyclopropanes
  • Galactosides
  • Immunoconjugates
  • Indoles
  • Prodrugs
  • beta-Galactosidase